AMGN vs REGN Stock Comparison: AI Score, Valuation, Performance and Upside
Amgen and Regeneron are both large biotechnology companies with diversified pipelines, with Amgen offering broader scale across oncology, inflammation, and an emerging obesity drug pipeline, while Regeneron leans on its proprietary antibody technology platform and eye disease franchise while diversifying into new therapeutic areas.
Amgen offers diversified scale plus emerging obesity drug pipeline optionality, while Regeneron offers a proven antibody technology platform with a durable but competitively pressured eye disease franchise. Consider whether you prefer Amgen's broader scale and obesity pipeline exposure or Regeneron's platform technology and franchise depth.
REGN holds the edge across 3 of 5 key metrics in this comparison. AMGN has delivered stronger 1-year price return (+55.67% vs +51.55%), though REGN has the better forward P/E setup (13.10x vs 15.46x for AMGN). On fundamentals, REGN is growing revenue faster (16.70%), while AMGN maintains the higher operating margin (35.55%) — a classic growth-versus-profitability split. Analyst consensus implies similar upside for both: +2.83% for AMGN and +5.82% for REGN.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want diversified exposure across oncology, inflammation, bone health, and cardiovascular treatments
- Believe the emerging obesity drug pipeline provides meaningful long-term growth optionality
- Value established large-scale manufacturing and commercial infrastructure
- Are comfortable with biosimilar competition affecting several legacy products over time
- Believe Regeneron's proprietary antibody technology platform will continue generating successful new drugs
- Value diversification into immunology and other therapeutic areas beyond the core eye disease franchise
- Are comfortable with ongoing competitive pressure on the eye disease franchise from biosimilar and alternative treatments
- Prefer a platform-technology-driven biotech over a broadly diversified large-cap biotech
| Metric | AMGN | REGN |
|---|---|---|
| AI scorei | 52.3 | 55.3 |
| AI ranki | #600 | #1048 |
| Latest closei | $461.26 | $973.36 |
| 1M returni | +14.45% | +32.39% |
| 3M returni | +18.27% | +27.96% |
| 6M returni | +39.95% | +38.60% |
| 1Y returni | +55.67% | +51.55% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | AMGN | REGN |
|---|---|---|
| 1Y ago | $15.55K (+55.5%) started 2025-11-04 | $15.5K (+55.0%) started 2025-11-04 |
| 5Y ago | $27.64K (+176.4%) started 2021-11-05 | $15.98K (+59.8%) started 2021-11-05 |
| 10Y ago | $58.09K (+480.9%) started 2016-11-07 | $26.75K (+167.5%) started 2016-11-07 |
Hypothetical — past performance does not guarantee future results.
| Metric | AMGN | REGN |
|---|---|---|
| Market capi | $204.01B | $81.77B |
| Trailing P/Ei | 23.42 | 19.65 |
| Forward P/Ei | 15.46 | 13.10 |
| Price/Salesi | 4.57 | 3.78 |
| EV/Revenuei | 6.49 | 4.76 |
| Analyst targeti | $388.03 | $840.43 |
| Target upsidei | +2.83% | +5.82% |
| Metric | AMGN | REGN |
|---|---|---|
| Revenue growthi | 9.50% | 16.70% |
| Earnings growthi | 64.90% | -4.50% |
| EPS growthi | +64.90% | -4.50% |
| FCF margini | +22.69% | +19.73% |
| Operating margini | 35.55% | 33.11% |
| Profit margini | 22.95% | 27.87% |
| ROIC proxyi | 91.47% | 14.04% |
| Return on equityi | 91.47% | 14.04% |
| Dividend yieldi | 2.64% | 0.47% |
| Payout ratioi | 60.87% | 8.18% |
| Dividend growth streaki | No increase yet | No increase yet |
| Betai | 0.43 | 0.19 |
| Debt/equityi | 490.28 | 8.54 |
| Current ratioi | 1.37 | 3.33 |
| Quick ratioi | 0.95 | 2.63 |
Over the past year, AMGN and REGN have moved moderately in the same direction (correlation of 0.44), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | AMGN | REGN |
|---|---|---|---|
| 1Y | Growthi | +55.46% | +54.99% |
| CAGRi | +55.56% | +55.09% | |
| Volatilityi | 29.73% | 36.12% | |
| Sharpe ratioi | 1.51 | 1.29 | |
| Sortino ratioi | 2.38 | 2.20 | |
| Max drawdowni | 16.57% | 26.05% | |
| Current drawdowni | 0.00% | 0.00% | |
| Avg drawdowni | 6.03% | 8.88% | |
| Ulcer Indexi | 7.71% | 11.49% | |
| Max daily dropi | 10.08% | 9.82% | |
| Max wkly dropi | 15.03% | 12.87% | |
| 5Y | Growthi | +143.32% | +59.61% |
| CAGRi | +19.48% | +9.81% | |
| Volatilityi | 24.93% | 32.06% | |
| Sharpe ratioi | 0.66 | 0.31 | |
| Sortino ratioi | 1.00 | 0.46 | |
| Max drawdowni | 24.86% | 59.69% | |
| Current drawdowni | 0.00% | 18.78% | |
| Avg drawdowni | 8.16% | 20.84% | |
| Ulcer Indexi | 10.34% | 28.45% | |
| Max daily dropi | 10.08% | 19.01% | |
| Max wkly dropi | 15.03% | 20.21% | |
| 10Y | Growthi | +330.92% | +167.13% |
| CAGRi | +15.74% | +10.33% | |
| Volatilityi | 25.14% | 32.63% | |
| Sharpe ratioi | 0.53 | 0.33 | |
| Sortino ratioi | 0.79 | 0.49 | |
| Max drawdowni | 24.86% | 59.69% | |
| Current drawdowni | 0.00% | 18.78% | |
| Avg drawdowni | 7.89% | 21.65% | |
| Ulcer Indexi | 9.77% | 27.15% | |
| Max daily dropi | 10.08% | 19.01% | |
| Max wkly dropi | 15.03% | 20.21% |
| Category | AMGN | REGN |
|---|---|---|
| Company | Amgen Inc. | Regeneron Pharmaceuticals, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Biotechnology |
| Core business | A large biotechnology company with a diversified portfolio spanning oncology, inflammation, bone health, and cardiovascular treatments, alongside an emerging pipeline in obesity and other high-growth therapeutic areas. | A biotechnology company known for its eye disease treatment franchise, alongside a growing portfolio of immunology, oncology, and other therapeutic treatments developed using its proprietary antibody technology platform. |
| Investor focus | Biosimilar competition impact on legacy products, obesity drug pipeline development progress, and newer product growth trends across oncology and inflammation categories. | Eye disease franchise competitive dynamics amid biosimilar and alternative treatment competition, newer drug pipeline contributions, and overall revenue diversification pace. |
- Diversified therapeutic area portfolio spans oncology, inflammation, bone health, and cardiovascular treatments, reducing single-franchise reliance
- Emerging obesity drug pipeline provides exposure to one of the fastest-growing therapeutic categories in the industry
- Established large-scale manufacturing and commercial infrastructure support efficient new product launches
- Proprietary antibody technology platform has supported a strong track record of successful drug discovery and development
- Growing immunology and other therapeutic area drugs provide diversification beyond the core eye disease franchise
- Established commercial infrastructure and physician relationships support new product launch execution
- Biosimilar competition affects several legacy products as patent exclusivity periods expire across the portfolio
- Obesity drug pipeline faces intense competitive pressure from other well-resourced pharmaceutical companies pursuing the same category
- Large, diversified portfolio requires successful execution across multiple therapeutic areas simultaneously to sustain growth
- Core eye disease franchise faces increasing competitive pressure from biosimilar and alternative treatment options
- Revenue diversification into newer therapeutic areas requires sustained successful clinical and commercial execution
- Competitive biopharmaceutical landscape across immunology and other pursued therapeutic areas includes numerous large competitors
Compare more than two at a time
This page is a fixed writeup on AMGN and REGN. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside AMGN and REGN, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.